Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8388641 | 0.88 | RIPK1 (0.48) | CES2CES1BCHERIPK1CXCL8 | |
| SCHEMBL14402655 | 0.85 | RIPK1 (0.46) | CES2CES1BCHERIPK1MEN1 | |
| SCHEMBL6967661 | 0.85 | CES2 (0.47) | CES2CES1BCHERIPK1CXCL8 | |
| SCHEMBL723768 | 0.85 | CXCL8 (0.56) | CES2CES1BCHERIPK1CXCL8 | |
| SCHEMBL11205828 | 0.83 | RIPK1 (0.46) | CES2CES1BCHERIPK1CXCL8 | |
| SCHEMBL4599084 | 0.83 | CES2 (0.45) | CES2CES1BCHERIPK1CXCL8 | |
| SCHEMBL29718813 | 0.83 | CES2 (0.45) | CES2CES1BCHERIPK1CXCL8 | |
| SCHEMBL1142802 | 0.83 | CES2 (0.45) | CES2CES1BCHERIPK1CXCL8 | |
| SCHEMBL6301587 | 0.83 | CES2 (0.45) | CES2CES1BCHERIPK1CXCL8 | |
| SCHEMBL28134586 | 0.83 | CXCL8 (0.54) | CES2CES1BCHERIPK1CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797842-B2 | BY ASYMMETRICALLY REDUCING AN OPTICALLY ACTIVE IMINE, USING A HYDRIDE REDUCING AGENT TO CONVERT TO AN OPTICALLY ACTIVE SECONDARY AMINE, WHICH THEN UNDERGOES HYDROGENOLYSIS; HIGH OPTICAL PURITY, SIMPLE, EFFICIENT | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-09-28 | — | — | US | disclosed |
| WO-2004020439-A2 | IMPROVED PROCESS FOR PREPARATION OF RISPERIDONE | NADKARNI SUNIL SADANAND (IN) | 2004-03-11 | — | — | WO | disclosed |
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | MAP2K5, MAP2K4, MAP2K1 | CES2 2291/4885CES1 984/4885BCHE 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.